Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
FEMASYS Aktie jetzt für 0€ handeln | |||||
25.09. | Femasys Inc.: Femasys Accelerates European Growth for FemBloc with Kebomed Partnership | 1 | GlobeNewswire (USA) | ||
22.09. | Femasys Inc.: Femasys Partners with Medical Electronic Systems to Launch FemSperm Analysis Kit for use with FemaSeed | 3 | GlobeNewswire (USA) | ||
11.09. | Femasys Inc.: Femasys Expands FemSperm Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed | 2 | GlobeNewswire (USA) | ||
08.09. | Femasys Inc.: Femasys Secures Regulatory Approval for FemBloc Permanent Birth Control in New Zealand | 3 | GlobeNewswire (USA) | ||
02.09. | Femasys Inc.: Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios | 2 | GlobeNewswire (USA) | ||
27.08. | Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale | 1 | Insider Monkey | ||
27.08. | Femasys Prices $8 Mln Public Offering To Fund Product Development And Commercial Expansion | 4 | RTTNews | ||
26.08. | Femasys-Aktie bricht nach Kapitalerhöhung mit hohem Abschlag ein | 5 | Investing.com Deutsch | ||
26.08. | Femasys stock plunges after pricing public offering at steep discount | 1 | Investing.com | ||
26.08. | Femasys stock falls after pricing capital raise of $8M via securities offering | 2 | Seeking Alpha | ||
26.08. | Femasys prices $8 million public offering to fund growth initiatives | 3 | Investing.com | ||
26.08. | Femasys: Kapitalerhöhung über 8 Millionen US-Dollar soll Wachstum finanzieren | 3 | Investing.com Deutsch | ||
26.08. | Femasys Inc.: Femasys Announces Pricing of $8.0 Million Underwritten Public Offering | 3 | GlobeNewswire (USA) | ||
21.08. | FEMASYS INC - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
21.08. | Femasys Inc.: Femasys Announces FemSperm Kit to Activate Gynecologists and Advance FemaSeed Fertility Platform | 2 | GlobeNewswire (USA) | ||
20.08. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
20.08. | Femasys Inc.: Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control | 263 | GlobeNewswire (Europe) | --Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility... ► Artikel lesen | |
20.08. | FEMASYS INC - S-1, General form for registration of securities | - | SEC Filings | ||
11.08. | Femasys: EPS erfüllt Schätzungen - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
11.08. | Femasys GAAP EPS of -$0.16 | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
UNITEDHEALTH | 303,05 | +0,41 % | HeraMED beschleunigt seinen KI-Fahrplan - Die nächste Phase der Frauengesundheit beginnt jetzt | ||
INTUITIVE SURGICAL | 379,60 | +0,41 % | Opening Bell: Puma, Novo Nordisk, Droneshield, Rio Tinto, Robinhood, Intuitive Surgical | Alle Jahre wieder droht in den USA der Regierungsshutdown. Auch dieses Jahr. Demokraten und Republikaner haben sich noch nicht auf einen Haushalt geeinigt. Auswirkungen an der Börse waren noch nicht... ► Artikel lesen | |
THERMO FISHER | 447,05 | -0,21 % | Thermo Fisher Scientific Inc.: Thermo Fisher Scientific gibt Forschungskooperation mit AstraZeneca BioVentureHub bekannt | Der Geschäftsbereich PPD Clinical Research von Thermo Fisher Scientific, dem weltweit führenden Anbieter von wissenschaftlichen Dienstleistungen, hat heute eine neue Forschungs- und Entwicklungspartnerschaft... ► Artikel lesen | |
ROKU | 88,34 | -0,29 % | Cathie Wood's ARK ETF adjusts portfolio, buys Baidu and sells Roku stock | ||
ATOSSA THERAPEUTICS | 0,792 | +0,76 % | Atossa Therapeutics appoints Janet Rea as SVP of R&D | ||
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting | -- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc.... ► Artikel lesen | |
CENTENE | 31,400 | -0,08 % | Centene-Aktie: Kurs nur geringfügig im Minus (29,6357 €) | Am US-amerikanischen Aktienmarkt ist das Wertpapier von Centene aktuell unauffällig. Die Aktie notiert gegenwärtig bei 34,76 US-Dollar. Kaum auffällig ist derzeit an der Börse der Kurs von Centene.... ► Artikel lesen | |
VERU | 3,825 | 0,00 % | These small cap stocks are poised for a comeback - Palisade Capital's Dan Veru | ||
QUIDELORTHO | 26,600 | -2,92 % | QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test | ||
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
NANO-X IMAGING | 3,785 | 0,00 % | Nano-X Imaging LTD.: Nanox Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC | Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technologyClinical studies show superior diagnostic performance to X-ray with reduced radiation exposure compared to CT PETACH... ► Artikel lesen | |
FULGENT GENETICS | 19,500 | -0,51 % | Fulgent Genetics: A Risky Bet or a Hidden Gem? | ||
LANTHEUS | 45,110 | +0,31 % | GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent | ||
PERSPECTIVE THERAPEUTICS | 2,960 | -1,33 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors | SEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments... ► Artikel lesen | |
AMN HEALTHCARE SERVICES | 16,400 | +3,14 % | AMN Healthcare Services Inc: AMN Healthcare Announces Second Quarter 2025 Results | Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc.... ► Artikel lesen |